The board of directors of China Isotope & Radiation Corporation announced that, recently, upon formal approval by the National Medical Products Administration, Shenzhen Zhonghe Headway Bio-Sci & Tech Co. Ltd. has successfully obtained the approval notice of drug clinical trial for its new C-urea breath test kit. Since the implementation of new regulations for drug management in the Opinions on Deepening the Reform of Evaluation and Approval System to Encourage Innovation in Drugs and Medical Devices issued by the General Office of the CPC Central Committee and the General Office of the State Council in 2017, the new C-urea breath tests developed by CNNC Headway has been the first-in-class drug applying for and obtaining the approval notice of clinical trial in China.

CNNC Headway adheres to the new development path of research and development to drive innovation, continuously developing new drugs to further enhance its core competitiveness.